Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma

Franck Morschhauser, Angelika Bischof-Delaloye, Ama Z. S. Rohatiner, Gilles Andre Salles, Jens Kuhlmann, Willem J. L. Van Putten, John Radford, Pierre Soubeyran, Achiel Van Hoof, Anton Hagenbeek

    Research output: Contribution to journalArticlepeer-review

    Original languageUndefined
    Pages (from-to)698-698
    Number of pages1
    Issue number11
    Publication statusPublished - 2008

    Cite this